

# UC Davis

## UC Davis Previously Published Works

### Title

Flucytosine resistance in *Cryptococcus gattii* is indirectly mediated by the FCY2-FCY1-FUR1 pathway

### Permalink

<https://escholarship.org/uc/item/35w720mt>

### Journal

Medical Mycology, 56(7)

### ISSN

1369-3786

### Authors

Vu, Kiem

Thompson, George R

Roe, Chandler C

et al.

### Publication Date

2018-10-01

### DOI

10.1093/mmy/myx135

Peer reviewed



Original Article

# Flucytosine resistance in *Cryptococcus gattii* is indirectly mediated by the FCY2-FCY1-FUR1 pathway

Kiem Vu<sup>1</sup>, George R. Thompson, III<sup>2,3</sup>, Chandler C. Roe<sup>4</sup>, Jane E. Sykes<sup>5</sup>, Elizabeth M. Dreibe<sup>4</sup>, Shawn R. Lockhart<sup>6</sup>, Wieland Meyer<sup>7</sup>, David M. Engelthaler<sup>4</sup> and Angie Gelli<sup>1,\*</sup>

<sup>1</sup>Department of Pharmacology, University of California, Davis, California, USA, <sup>2</sup>Department of Medical Microbiology and Immunology, University of California, Davis, California, USA, <sup>3</sup>Department of Internal Medicine, Division of Infectious Diseases, University of California Davis Medical Center, Davis, California, USA, <sup>4</sup>Translational Genomics Research Institute, Flagstaff, Arizona, USA, <sup>5</sup>Department of Medicine and Epidemiology, School of Veterinary Medicine, University of California, Davis, California, USA, <sup>6</sup>Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia USA and <sup>7</sup>Molecular Mycology Research Laboratory, Center for Infectious Diseases and Microbiology, Marie Bashir Institute for Emerging Infectious Diseases and Biosecurity, Westmead Clinical School, Sydney Medical School, Westmead Hospital, The University of Sydney, Westmead Institute for Medical Research, Sydney, Australia

\*To whom correspondence should be addressed. Angie Gelli, PhD, Department of Pharmacology, School of Medicine University of California, Davis Genome and Biomedical Sciences Facility Davis, CA 95616 USA. Tel: 530-754-6446; Fax: 530-754-5217; E-mail: [acgelli@ucdavis.edu](mailto:acgelli@ucdavis.edu)

Received 12 June 2017; Revised 12 October 2017; Editorial Decision 24 October 2017

## Abstract

Cryptococcosis is an opportunistic fungal infection caused by members of the two sibling species complexes: *Cryptococcus neoformans* and *Cryptococcus gattii*. Flucytosine (5FC) is one of the most widely used antifungals against *Cryptococcus* spp., yet very few studies have looked at the molecular mechanisms responsible for 5FC resistance in this pathogen. In this study, we examined 11 *C. gattii* clinical isolates of the major molecular type VGIII based on differential 5FC susceptibility and asked whether there were genomic changes in the key genes involved in flucytosine metabolism. Susceptibility assays and sequencing analysis revealed an association between a point mutation in the cytosine deaminase gene (*FCY1*) and 5FC resistance in two of the studied 5FC resistant *C. gattii* VGIII clinical isolates, B9322 and JS5. This mutation results in the replacement of arginine for histidine at position 29 and occurs within a variable stretch of amino acids. Heterologous expression of *FCY1* and spot sensitivity assays, however, demonstrated that this point mutation did not have any effect on *FCY1* activities and was not responsible for 5FC resistance. Comparative sequence analysis further showed that no changes in the amino acid sequence and no genomic alterations were observed within 1 kb of the

upstream and downstream sequences of either cytosine permeases (*FCY2-4*) or uracil phosphoribosyltransferase (*FUR1*) genes in 5FC resistant and 5FC susceptible *C. gattii* VGIII isolates. The herein obtained results suggest that the observed 5FC resistance in the isolates B9322 and JS5 is due to changes in unknown protein(s) or pathway(s) that regulate flucytosine metabolism.

**Key words:** *Cryptococcus gattii*, flucytosine resistance, cytosine deaminase, *FCY1*.

## Introduction

Members of the *Cryptococcus neoformans* and *Cryptococcus gattii* species complexes are the etiological agents of cryptococcosis. While *C. neoformans* is responsible for most cases of infections globally, *C. gattii* continues to pose a serious public health threat, as witnessed by ongoing cases of infections in the Pacific Northwest region of Canada and the United States since 1999.<sup>1</sup> Despite global concerns, a limited number of antifungals are effective against *Cryptococcus* spp., and resistance to these drugs is common in clinical settings.<sup>2</sup> Current therapeutic options for the treatment of cryptococcosis include amphotericin B formulations, flucytosine, and the triazoles.<sup>2</sup> Flucytosine (5-fluorocytosine, 5FC) is a fluorinated pyrimidine with activity against a number of fungal pathogens. It has no intrinsic antifungal capacity, but after uptake by susceptible fungi it is converted into 5-fluorouracil (5FU), which is further converted into metabolites that inhibit fungal RNA and DNA synthesis. 5FC combined with amphotericin B is currently the gold standard for the treatment of cryptococcal meningoencephalitis,<sup>3</sup> and reduced mortality with the use of this regimen has been demonstrated in a randomized trial.<sup>4</sup>


It is well known that flucytosine metabolism utilizes the pyrimidine salvage pathway that operates in fungal and bacterial species. Mutations in three key components of this pathway have been implicated in promoting flucytosine resistance in fungal species: cytosine permease (*FCY2*), cytosine deaminase (*FCY1*), and uracil phosphoribosyltransferase (UPRTase, encoded by *FUR1*).<sup>5,6</sup> Flucytosine is transported into susceptible fungi by the membrane-bound cytosine permease and subsequently deaminated to 5-fluorouracil (5FU) by cytosine deaminase (Fig. 1). The absence of cytosine deaminase in mammalian cells allows selective toxicity on fungal organisms. Following deamination of 5FC, 5FU is converted into 5-fluorouridine monophosphate (FUMP) via the action of UPRTase. FUMP is then further reduced to 5-fluorodeoxyuridine monophosphate (FdUMP), which interferes with DNA synthesis. Inhibition of protein synthesis occurs through a separate mechanism where FUMP is phosphorylated to become 5-fluorouridine diphosphate (FUDP) and 5-fluorouridine triphosphate (FUTP), which is in turn incorporated into fungal RNA, thereby disrupting the amino acid pool and ultimately causing abnormal protein synthesis.

Due to the high incidence of acquired or primary (intrinsic) resistance, the use of 5FC as monotherapy is not recommended except in selected cases of urinary candidiasis and chromoblastomycosis.<sup>3,7</sup> Acquired resistance is often due to a decrease in UPRTase activity and is most frequently found following treatment with 5FC.<sup>8</sup> This resistance is thought to be a result of either the failure of the organism to metabolize the drug or the loss of pyrimidine biosynthesis feedback control.<sup>8</sup> On the other hand, primary resistance is thought to be the result of impaired cellular deamination or decreased 5FC uptake due to mutations in the *FCY1* or *FCY2* genes respectively.<sup>9</sup> At the present time, there is a paucity of data on the regulatory and resistance mechanisms of 5FC in *Cryptococcus* spp. A recent genome-scale study on the regulatory and resistance mechanisms of 5FC in *C. neoformans* identified 177 5FC responsive genes.<sup>10</sup> In particular, a *C. neoformans* strain lacking the transcription factor, Mbs1, displayed increased susceptibility to 5FC.<sup>10</sup> On the other hand, the 5FC resistance mechanisms have not been previously explored in *C. gattii* at the molecular level, and it is generally thought that they are similar to those found in *Saccharomyces cerevisiae* and *Candida albicans*.<sup>8</sup> In the herein presented work, we tested 11 *C. gattii* clinical and veterinary isolates belonging to the major molecular type VGIII/AFLP5 for 5FC susceptibility and identified two resistant isolates with 5FC MIC > 64 µg/ml. Our data surprisingly show that the observed 5FC resistance did not directly involve changes in either protein sequences or upstream and downstream genomic sequences of cytosine permeases, cytosine deaminase, or uracil phosphoribosyltransferase genes. We speculate that the 5FC resistance in the two examined *C. gattii* VGIII clinical isolates, B9322 and JS5, is due to changes in regulatory protein(s) or pathway(s) that control flucytosine metabolism.

## Methods

### Reagents, isolates, and culture conditions

Flucytosine (5FC) (Cat. F7129) and cytosine (Cat. C3506) were obtained from Sigma. All 11 *C. gattii* strains were grown and maintained on yeast-peptone-dextrose (YPD) medium. 5FC resistant *C. gattii* VGIII strains (B9322 and JS5) and susceptible strains (JS91 and those with MICs < 4 µg/ml shown in Table 1) were obtained from a



**Figure 1.** The main enzymatic steps involved in the uptake, conversion, and mechanism of action of fluoropyrimidines. 5FC, flucytosine; 5FU, 5-fluorouracil; UPRtase/FUR1, uracil phosphoribosyltransferase; FUMP, 5-fluorouridine monophosphate; FUDP, 5-fluorouridine diphosphate; FUTP, 5-fluorouridine triphosphate; FdUMP, 5-fluorodeoxyuridine monophosphate. This Figure is reproduced in color in the online version of *Medical Mycology*.

**TABLE 1.** *In vitro* susceptibility testing and FCY1 profiles of 11 *Cryptococcus gattii* clinical and veterinary isolates used in this study.

Strains ID	Other Collection numbers	Country	Year of isolation	Source	Serotype	Mating Type	FCY1 Sequence (5' → 3')	Mutations	5FC MIC (ug/mL)	Original Reference
B9322	WM1.1.949	USA	2011	clin	B	alpha	TTGAAGAGTCATTTCG	LKSHS	>64	Ref 13
JS5	WM10.165	USA	2005	vet	B	alpha	TTGAAGAGTCATTTCG	LKSHS	>64	Ref 12
JS69	WM10.186	USA	2006	vet	B	alpha	TTGAAGAGTCGTTTCG	LKSRS	0.5	Ref 14
JS91	WM11.40	USA	2011	vet	C	a	TTGAAGAGCCGTTTCG	LKSRS	0.5	Ref 14
JS110	WM11.139	USA	2011	vet	B	a	TTGAAGAGCCGTTTCG	LKSRS	1	Ref 12
B8965	WM11.941	USA	2010	clin	B	a	TTGAAGAGCCGTTTCG	LKS RS	1	Ref 13
B9151	WM1.1.945	USA	2011	clin	B	alpha	TTGAAGAGCCGTTTCG	LKSRS	1	Ref 12
B8260	WM1.1.937	USA	2009	vet	C	alpha	TTGAAGAGCCGTTTCG	LKSRS	0.5	Ref 13
B8262	WM1.1.938	USA	1992	clin	B	alpha	TTGAAGAGICGTTTCG	LKSRS	1	Ref 15
07-11763	WM09.45	USA	2007	vet	B	alpha	TTGAAGAGICGTTTCG	LKS RS	1	Ref 12
08-7686	WM09.47	USA	2008	vet	B	alpha	TTGAAGAGICGTTTCG	LKSRS	0.5	Ref 12

collection of clinical and veterinary *C. gattii* isolates.<sup>11–15</sup> The *S. cerevisiae* WT and mutant strain lacking cytosine deaminase (*Sc fcy1Δ*) were a gift from Joseph Heitman (Duke University).<sup>16</sup>

### Genome sequencing and *in vitro* susceptibility testing of *C. gattii* clinical isolates

Isolates included in this study all belong to the *C. gattii* VGIII major molecular type and had previously undergone whole genome sequencing as part of a larger population genomics survey.<sup>11–15</sup> Isolates with differential 5FC susceptibility were chosen for comparison, and genomic sequences of regions predicted to be involved in 5FC

susceptibility were compared (see Table 2). Susceptibility testing was performed on 11 *C. gattii* VGIII isolates in accordance with the CLSI reference document M27-A3.<sup>17</sup> *Candida krusei* ATCC 6258 and *Candida parapsilosis* ATCC 22019 were used as controls for susceptibility testing. The strains JS5 and B9322 showing 5FC MICs >64 μg/ml were chosen for comparison to nine isolates with 5FC MICs <4 μg/ml (Table 1).

### Spot sensitivity assays

5FC and 5FU resistance assays were carried out on minimal media (SD) supplemented with 2.5–10 μg/ml 5FC or 1–10 μg/ml 5FU, respectively. Cytosine assimilation assays

**Table 2.** List of putative *Cryptococcus gattii* genetic loci involved in cytosine metabolism.

<i>C. gattii</i> genes	Broad institute ID	Amino acid changes
Cytosine deaminase ( <i>FCY1</i> )	CNAG.00613.2	R29H mutation in two isolates
Cytosine permease ( <i>FCY2</i> )	CNAG.01681.2	No change
Cytosine-purine permease, ( <i>FCY3</i> )	CNAG.04982.2	No change
Cytosine permeases ( <i>FCY4</i> )	CNAG.04276.2	No change
Uracil phosphoribosyltransferase ( <i>FUR1</i> )	CNAG.02337.2	No change

were done on minimal media lacking a nitrogen source (without  $\text{NH}_4\text{SO}_4$ ) and supplemented with 1–4 mM cytosine. Sterile-filtered stock solutions of 5FC (5.2  $\mu\text{g}/\text{ml}$ ), 5FU (5.0  $\mu\text{g}/\text{ml}$ ), and cytosine (40 mM) were prepared by dissolving the powder in  $\text{ddH}_2\text{O}$  or DMSO (as the case for 5FU) and added to SD agar post-autoclave. Inocula from overnight cultures were used to start new cultures for 8–10 hours on the day of the experiment. Cultures were washed three times with 1X phosphate-buffered saline (PBS) and resuspended in 1X PBS. Serial 10-fold dilutions were prepared ( $10^1$  cells/ $5 \mu\text{l}$  to  $10^5$  cells/ $5 \mu\text{l}$ ) on 96-well plates, and  $5 \mu\text{l}$  of each dilution was spotted on assay plates using a multichannel pipet.

#### Heterologous expression of *C. gattii* *FCY1* in yeast

*C. gattii* *FCY1* wild-type (Cg $FCY1^{\text{wt}}$ ) and *FCY1* mutant (Cg $FCY1^{\text{mut}}$ ) complementary DNAs (cDNAs) were ordered from GenScript Inc., Piscataway, NJ, USA. The Cg $FCY1^{\text{mut}}$  cDNA carried a point mutation at nucleotide position 86, resulting in the Arg29His substitution in the expressed protein. Both wild-type and mutant cDNAs were commercially synthesized and subcloned into the pUC57 plasmid backbone. To produce the yeast heterologous expression constructs expressing either Cg $FCY1^{\text{wt}}$  or Cg $FCY1^{\text{mut}}$  cDNA under the control of either a strong GDP promoter or a weak ADH promoter, pUC57 plasmids carrying Cg $FCY1$  cDNAs were digested with *Bam*HI and *Eco*RI, and the gel purified cDNAs were subcloned into the yeast shuttle expression plasmids p416GDP and p416ADH (Fig. S1).<sup>18</sup> The resultant expression plasmids were then introduced into *S. cerevisiae* *fcy1* $\Delta$  via lithium acetate transformation using a standard method.<sup>19</sup> Transformants were selected on uracil-deficient medium and tested for their ability to assimilate cytosine and grow on SD media in the presence of flucytosine.

#### Heterologous expression of *C. gattii* *FCY1* in the KN99 *fcy1* $\Delta$ background

*C. gattii* *FCY1* wild-type (Cg $FCY1^{\text{wt}}$ ) and *FCY1* mutant (Cg $FCY1^{\text{mut}}$ ) cDNAs and *C. neoformans* *FCY1* wild-type (Cn $FCY1^{\text{wt}}$ ) and *FCY1* mutant (Cn $FCY1^{\text{mut}}$ ) cDNAs were


subcloned into the Jmm180 *Cryptococcus* expression plasmid under the control of the constitutive actin promoter (Fig. S1). The resultant expression plasmids were then introduced into the KN99 *FCY1* deletion strain (KN99 *fcy1* $\Delta$ ) via biolistic transformation.<sup>20</sup> Transformants were selected on uracil-deficient medium and tested on minimal media (SD) in the presence of flucytosine and assimilate cytosine as a sole nitrogen source.

## Results

Mutations in the proteins that mediate the uptake or metabolism of flucytosine (5FC) are the basis for 5FC resistance.<sup>6,21</sup> Primary resistance, the focus of this study, refers to the inherent resistance in the absence of prior drug exposure. We investigated primary resistance in *C. gattii* VGIII isolates to 5FC by identifying and analyzing genomic sequences of cytosine permease genes (*FCY2*, *FCY3*, *FCY4* – 3 putative genes found in *C. gattii*), cytosine deaminase gene (*FCY1*), and uracil phosphoribosyltransferase (UPRTase, encoded by *FUR1*) in 11 clinical isolates (Table 2). These transporters and enzymes are the major components of the pyrimidine salvage pathway found in fungi and bacteria and are known to play essential roles in 5FC metabolism (Fig. 1). Susceptibility testing and sequence analysis of 11 *C. gattii* isolates revealed an association between a point mutation in the *FCY1* gene and 5FC resistance in two clinical isolates (B9322 and JS5) where the substitution of guanine for adenine at nucleotide position 86 resulted in the exchange of arginine for histidine at the amino acid position 29 (Table 1). Comparative analysis of the open reading frames (ORF) and the 1 kb upstream and downstream sequences of the three putative cytosine permeases (*FCY2-4*) and UPRTase (*FUR1*) between the 5FC resistant and susceptible isolates indicated that these genes were either isogenic or displayed silent mutations (Table 2) (Fig. S2). Together, our data suggested that a single point mutation in *FCY1* may have given rise to 5FC resistance in the isolates B9322 and JS5.

The enzyme structure of cytosine deaminase in *S. cerevisiae* has been resolved.<sup>22,23</sup> The structure predicts that among the *FCY1* active-site residues, a histidine and two cysteines (highlighted in yellow) coordinate zinc within the






**Figure 4.** Heterologous expression of *C. gattii* FCY1 wildtype (CgFCY1<sup>wt</sup>) and FCY1 mutant (CgFCY1<sup>mut</sup>) proteins under the control of the strong GDP promoter in the *S. cerevisiae fcy1*Δ genetic background (ScΔ). (A) Growth of *S. cerevisiae* wildtype, *fcy1*Δ, and heterologously expressed strains on minimal media (SD) in the presence of 2.5–10 µg/ml flucytosine (5FC). (B) Growth of *S. cerevisiae* strains on minimal media containing 1–4 mM cytosine as a sole nitrogen source. SD(-N) denotes synthetic dextrose agar lacking a nitrogen source.

cytosine deaminase (*S. cerevisiae fcy1*Δ) and showed that it was highly resistant to 5FC as predicted (Fig. 3A).


Since the deamination of cytosine to uracil results in the production of ammonia, the ability of fungi to assimilate cytosine as a sole nitrogen source has been used as a proxy method to quickly determine the presence of cytosine deaminase activity.<sup>21</sup> Surprisingly, we found that despite the point mutation in the *FCY1* gene and the observed 5FC resistance, both isolates, B9322 and JS5, grew robustly on media containing cytosine as the sole nitrogen source suggesting that the Arg29His substitution has little to no effect on cytosine deaminase activity (Fig. 3B). We suspected that the Arg29His substitution may alter the overall FCY1 structure in such a manner that the enzyme becomes defective at metabolizing 5FC (thus giving rise to 5FC resistance) while retaining its ability to assimilate cytosine. To test this idea, both wild-type and mutant *FCY1* cDNAs from *C. gattii* were heterologously expressed in the *S. cerevisiae fcy1*Δ genetic background under the control of the strong GDP promoter, and the yeast transformants were tested for their susceptibility to flucytosine and their ability to assimilate cytosine (Fig. 4). Contrary to our expectation, *S. cerevisiae fcy1*Δ cells expressing the mutant cytosine deaminase (CgFCY1<sup>mut</sup>) were susceptible to flucytosine and grew on cytosine media to the same extent as

those expressing the wildtype version (CgFCY1<sup>wt</sup>), suggesting that the Arg29His substitution has no effect on cytosine deaminase activity. While the heterologous expression data indicated that there was no causal link between the Arg29His substitution in FCY1 and the 5FC resistance observed in the isolates B9322 and JS5, we thought that expressing the mutant FCY1 protein (CgFCY1<sup>mut</sup>) under the control of a strong promoter might have masked any differences we observed between wild-type and mutant proteins. To rule out this possibility, CgFCY1<sup>wt</sup> and CgFCY1<sup>mut</sup> proteins were heterologously expressed in the *S. cerevisiae fcy1*Δ genetic background under the control of the weak ADH promoter (Fig. 5). The ADH promoter had previously been assayed to have activities that were 72 times less than the activities associated with the GDP promoter.<sup>18</sup> Despite the low expression, *S. cerevisiae fcy1*Δ cells expressing the CgFCY1<sup>mut</sup> protein were susceptible to 5FC and able to assimilate cytosine to the same level as those expressing the wild-type version (CgFCY1<sup>wt</sup>) (Fig. 5). The similar 5FC susceptibility observed between transformants expressing either CgFCY1<sup>wt</sup> or CgFCY1<sup>mut</sup> protein held true even over a subtle range of 5FC concentrations (Fig. 6).

To further rule out the unlikely scenario that the CgFCY1<sup>mut</sup> protein may behave unpredictably when




**Figure 5.** Heterologous expression of *C. gattii* FCY1 wildtype (CgFCY1<sup>wt</sup>) and FCY1 mutant (CgFCY1<sup>mut</sup>) proteins under the control of the weak ADH promoter in the *S. cerevisiae fcy1*Δ genetic background (ScΔ). (A) Growth of *S. cerevisiae* wildtype, *S. cerevisiae fcy1*Δ, and heterologously expressed strains on minimal media (SD) in the presence of 2.5–10 µg/ml flucytosine (5FC). (B) Growth of *S. cerevisiae* strains on minimal media containing 1–4 mM cytosine as a sole nitrogen source. SD(-N) denotes synthetic dextrose agar lacking a nitrogen source.



**Figure 6.** Heterologous expression of *C. gattii* FCY1 wildtype (CgFCY1<sup>wt</sup>) and FCY1 mutant (CgFCY1<sup>mut</sup>) proteins under the control of the weak ADH promoter in the *S. cerevisiae fcy1*Δ genetic background (ScΔ). Growth of *S. cerevisiae* wild-type, *S. cerevisiae fcy1*Δ, and heterologously expressed strains on minimal media (SD) in the presence of 0.0025–0.16 µg/ml flucytosine (5FC).






**Figure 7.** Expression of *C. neoformans* and *C. gattii* FCY1 wildtype and FCY1 mutant proteins under the control of the actin promoter in the KN99 *fcy1*Δ genetic background (KN99Δ). Growth of KN99 wildtype, KN99 *fcy1*Δ, and heterologously expressed strains on minimal media (SD) in the presence of 5 μg/ml flucytosine (5FC) or 4 mM cytosine as a sole nitrogen source. CgFCY1<sup>wt</sup>/CgFCY1<sup>mut</sup> and CnFCY1<sup>wt</sup>/CnFCY1<sup>mut</sup> denote FCY1 wild-type and mutant proteins from *C. gattii* and *C. neoformans*, respectively. SD(-N) denotes synthetic dextrose agar lacking a nitrogen source.

expressed in *S. cerevisiae*, both CgFCY1<sup>wt</sup> and CgFCY1<sup>mut</sup> proteins were expressed in the KN99 *fcy1*Δ genetic background and transformants were tested for flucytosine susceptibility and their ability to assimilate cytosine (Fig. 7). We decided to heterologously express the *C. gattii* FCY1 proteins in the KN99 *fcy1*Δ genetic background because the strain KN99 belongs to *C. neoformans*, a sibling species of *C. gattii* and the KN99 *fcy1*Δ null mutant had recently been made available to the scientific community.<sup>25</sup> Similar to the results obtained from the *S. cerevisiae* heterologous system, no differences in flucytosine susceptibility and cytosine assimilation were observed between KN99 *fcy1*Δ transformants expressing either the CgFCY1<sup>wt</sup> or CgFCY1<sup>mut</sup> proteins (Fig. 7). In addition, the KN99 FCY1 mutant allele, CnFCY1<sup>mut</sup>, was also generated and expressed in the KN99 *fcy1*Δ genetic background. As expected, transformants expressing the mutant FCY1 protein from KN99 were found to restore flucytosine susceptibility and cytosine assimilation to wildtype level (Fig. 7).

To assess whether the observed flucytosine resistance in B9322 and JS5 is due to pathway components downstream of FCY1, the isolates were tested for their ability to grow on 5-fluorouracil (5FU), a toxic metabolite that normally forms as a result of the deamination of 5FC (Fig. 1). Consistent with the contribution of FUR1 to flucytosine resistance, both isolates B9322 and JS5 were able to survive on 5FU over a wide concentration range (Fig. 8). Several colonies from the 5FC susceptible isolate, JS91, could be observed growing on media containing 5FU; however, these were likely resistant cells that spontaneously arise during prolonged drug exposure. Interestingly, sequencing analysis revealed that there were no amino acid changes in FUR1 among 5FC resistant and 5FC susceptible isolates (Fig. S2). In addition, analysis of 1 kb of the upstream and downstream sequences of the *FUR1* gene did not show any genomic changes spanning the 2 kb genomic distance, except for the presence of several SNPs that are not unique to the B9322 and JS5 isolates (Fig. S3A,B).



**Figure 8.** B9322 and JS5 are resistant to 5-fluorouracil (5FU). Growth of 5FC resistant isolates (B9322 and JS5), 5FC susceptible isolate (JS91) and KN99 control strains (KN99 WT and KN99 *fur1*Δ) on minimal media (SD) containing 5  $\mu$ g/ml 5FC or 1–10  $\mu$ g/ml 5FU. Serial dilutions of cells ( $10^5$  cells/5  $\mu$ l to  $10^1$  cells/5  $\mu$ l) were spotted on SD agar supplemented with either 5FC or 5FU.

## Discussion

Flucytosine (5FC) remains an essential adjunct to amphotericin B during the treatment of severe cryptococcal infections.<sup>4</sup> While the molecular mechanisms responsible for 5FC resistance have been well studied in *Candida* spp.<sup>5,6,21,24,26,27</sup> and *S. cerevisiae*<sup>28–31</sup>, little is known about the 5FC resistance mechanisms in *Cryptococcus* spp.<sup>8,10</sup> 5FC resistance has been previously described in *C. neoformans* and *C. gattii* VGIII isolates analyzed in epidemiological studies<sup>32,33</sup>; however, amino acid changes within key enzymes in the 5FC metabolic pathway have not yet been examined in these isolates. Primary 5FC resistance in *C. neoformans* has been reported to occur in 1–25% of isolates.<sup>5,34,35</sup> Unfortunately, past reports examining the mechanism of resistance in these strains have been limited and to our knowledge an assessment of 5FC resistance mechanism in *C. gattii* has not been previously performed.

Genotyping of *C. gattii* at subspecies level identified four major molecular types (VGI/AFLP4, VGII/AFLP6, VGIII/AFLP5, and VGIV/AFLP7) among *C. gattii* isolates.<sup>36</sup> The molecular type VGIII has received greater interest in recent years because it has been identified as the main cause of disease in otherwise healthy individuals.<sup>16</sup> Based on multilocus sequencing typing (MLST) analysis, *C. gattii* VGIII is subdivided into VGIIIa and VGIIIb subgroups with the VGIIIa isolates showing more virulence.<sup>16</sup> VGIIIa and VGIIIb have been shown to correspond to serotype B and serotype C, respectively.<sup>12</sup> Nine of the *C. gattii* VGIII isolates used in this study belong to the VGIIIa subgroup

(serotype B) and two isolates belong to the VGIIIb subgroup (serotype C) (Table 1). Based on the analysis of 55 isolates, *C. gattii* was recently proposed to be divided into five species.<sup>37</sup> However, this new nomenclature remains very controversial, leading to the proposal of leading members of the *Cryptococcus* research community to apply the term “species complex” in combination with the major molecular type designation until all scientific aspects concerning the different major genetic groups within the *C. gattii* species complex are available.<sup>38</sup> As a result, the current study is referring to the isolates used herein as *C. gattii* VGIII.

In the herein presented work, we identified an association between 5FC resistance and the Arg29His mutation found within the cytosine deaminase gene (*FCY1*) of two *C. gattii* VGIII clinical isolates, B9322 and JS5. This association is consistent with the role of *FCY1* as the enzyme responsible for the conversion of 5FC to 5FU (5-fluorouracil), a toxic metabolite that inhibits DNA and protein synthesis. Our finding is also in agreement with previous studies on 5FC resistance where deletion or mutations in the *FCY1* gene (also known as *FCA1* in *Candida* spp.) were found to contribute to 5FC resistance in both *Candida* spp.<sup>8,21,24,26</sup> and *S. cerevisiae*.<sup>29</sup> With the exception of the Arg29His mutation found in *FCY1* in the isolates B9322 and JS5, no amino acid changes were observed in either cytosine permeases (*FCY2-4*) or *FUR1*, suggesting that the Arg29His mutation may be responsible for the observed 5FC resistance (Table 2) (data not shown).

To assess the impact of the Arg29His mutation on FCY1 activities, the isolates B9322 and JS5 were tested on media containing cytosine as the sole nitrogen source. Since ammonia is the byproduct produced from the deamination of cytosine to uracil, assessing the ability of *C. gattii* to assimilate cytosine would establish whether the Arg29His mutation is essential for FCY1 activity.<sup>16</sup> Interestingly, both isolates B9322 and JS5 were found to grow robustly on cytosine media, suggesting the existence of active FCY1 in the resistant isolates (Fig. 3B). The finding that the isolates B9322 and JS5 can assimilate cytosine therefore nullified our hypothesis that the Arg29his mutation on FCY1 was responsible for their resistance to 5FC. An alternative interpretation of the cytosine assimilation data, however, could potentially rescue our hypothesis. We thought that the Arg29His mutation altered the overall FCY1 structure in such a manner that the enzyme was defective at metabolizing 5FC while retained its ability to assimilate cytosine. This notion is consistent with our finding that the Arg29His substitution occurs in a stretch of amino acids that is not conserved (Fig. 2). It is conceivable that a nonessential mutation reduces the affinity of cytosine deaminase to 5FC but not cytosine. To test this idea, we heterologously expressed the *C. gattii* FCY1 wild-type and mutant proteins (CgFCY1<sup>wt</sup> and CgFCY1<sup>mut</sup>) in both *S. cerevisiae* *fcy1*Δ and the *C. neoformans* KN99 *fcy1*Δ genetic backgrounds and assessed their resistance to 5FC and growth on cytosine media. Spot sensitivity data obtained from these heterologous expression studies unequivocally demonstrate that the Arg29His mutation has no effect on FCY1 activities towards either flucytosine or cytosine (Fig. 4–7). Thus, there is no causal link between the point mutation found in FCY1 and the observed 5FC resistance in the isolates B9322 and JS5.

Interestingly, the 5FC resistant isolates, B9322 and JS5, were viable on media containing 5-fluorouracil (5FU), a highly toxic metabolite that requires functional UPRTase (encoded by *FUR1*) for its antifungal activities. Analysis of *FUR1* among 5FC resistant and 5FC susceptible isolates showed that no amino acid changes and no genomic alterations were observed within 1 kb of the upstream and downstream sequences of the *FUR1* gene (Fig. S3A,B), suggesting that the observed 5FC resistance in *C. gattii* is likely due to changes in unknown protein(s) or pathway(s) that regulate *FUR1* expression. Consistent with this notion, DNA microarray data suggests that *FUR1* expression in *S. cerevisiae* is mediated by several positive regulators, including CAD1, CST6, and SSP1.<sup>8,39</sup>

While the data from this work did not yield any breakthrough in the understanding of the molecular mechanism responsible for 5FC resistance in two clinical isolates of *C. gattii*, they provide important insights into where we

should direct our efforts in order to better understand 5FC resistance in this important human pathogen. The majority of work done in *S. cerevisiae* and other fungal pathogens, particularly *Candida* spp., have focused on the three key mediators of flucytosine resistance—namely, cytosine permease (*FCY2*), cytosine deaminase (*FCY1*), and UPRTase (*FUR1*).<sup>5,6,8,21,24,27,40</sup> Mutations in either the coding sequence or the immediate upstream and downstream sequences flanking the *FCY2*, *FCY1*, and *FUR1* genes have been shown to promote flucytosine resistance in the above studies. The herein presented data suggest that the 5FC resistance in the isolates B9322 and JS5 is not mediated by changes in either the genes' coding or regulatory sequences but is likely be due to unknown factors or pathways that modulate flucytosine metabolism. Consistent with the notion that 5FC resistance can be mediated by changes in proteins that are not part of the pyrimidine salvage pathways is the deletion of the transcription factor MBS1 for which it has been shown that it confers increased susceptibility to 5FC in *C. neoformans*.<sup>10</sup> A recent genome-wide screen for genes that promote flucytosine resistance in *S. cerevisiae* identified over 180 genes, particularly those involved in DNA repair, RNA and protein metabolism.<sup>41</sup> These aforementioned studies and the herein presented work further underline the need to examine 5FC resistance mechanisms globally in order to arrive at a better understanding of 5FC resistance in fungal pathogens.

## Acknowledgments

We are especially grateful to Joseph Heitman (Duke University) for providing the *S. cerevisiae* WT and *fcy1*Δ deletion strains and to the National Institute of Allergy and Infectious Diseases (NIAID) for funding.

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

## Supplementary material

Supplementary data are available at [MMYCOL](http://www.mycology.org) online.

## Declaration of interest

The authors report no conflicts of interest. The authors alone are responsible for the content and the writing of the paper.

## References

1. Datta K, Bartlett KH, Baer R et al. Spread of *Cryptococcus gattii* into Pacific Northwest region of the United States. *Emerg Infect Dis*. 2009; 15: 1185–1191.
2. Coelho C, Casadevall A. Cryptococcal therapies and drug targets: the old, the new and the promising. *Cell Microbiol*. 2016; 18: 792–799.

3. Perfect JR, Dismukes WE, Dromer F et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. *Clin Infect Dis*. 2010; 50: 291–322.
4. Day JN, Chau TT, Wolbers M et al. Combination Antifungal Therapy for Cryptococcal Meningitis. *N Engl J Med*. 2013; 368: 1291–1302.
5. Cuenca-Estrella M, Diaz-Guerra TM, Mellado E, Rodriguez-Tudela JL. Flucytosine primary resistance in *Candida* species and *Cryptococcus neoformans*. *Eur J Clin Microbiol Infect Dis*. 2001; 20: 276–279.
6. Hope WW, Taberner L, Denning DW, Anderson MJ. Molecular mechanisms of primary resistance to flucytosine in *Candida albicans*. *Antimicrob Agents Chemother*. 2004; 48: 4377–4386.
7. Rex JH, Walsh TJ, Sobel JD et al. Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. *Clin Infect Dis*. 2000; 30: 662–678.
8. Whelan WL. The genetic basis of resistance to 5-fluorocytosine in *Candida* species and *Cryptococcus neoformans*. *Crit Rev Microbiol*. 1987; 15: 45–56.
9. Block ER, Jennings AE, Bennett JE. 5-fluorocytosine resistance in *Cryptococcus neoformans*. *Antimicrob Agents Chemother*. 1973; 3: 649–656.
10. Song MH, Lee JW, Kim MS et al. A flucytosine-responsive Mbp1/Swi4-like protein, Mbs1, plays pleiotropic roles in antifungal drug resistance, stress response, and virulence of *Cryptococcus neoformans*. *Eukaryotic cell*. 2012; 11: 53–67.
11. Engelthaler DM, Hicks ND, Gillece JD et al. *Cryptococcus gattii* in North American Pacific Northwest: whole-population genome analysis provides insights into species evolution and dispersal. *MBio*. 2014; 5: e01464–014714.
12. Firacative C, Roe CC, Malik R et al. MLST and whole-genome-based population analysis of *Cryptococcus gattii* VGIII links clinical, veterinary and environmental strains, and reveals divergent serotype specific sub-populations and distant ancestors. *PLoS Negl Trop Dis*. 2016; 10: e0004861.
13. Lockhart SR, Iqbal N, Harris JR et al. *Cryptococcus gattii* in the United States: genotypic diversity of human and veterinary isolates. *PLoS One*. 2013; 8: e74737.
14. Singer L.M., Meyer W., Firacative C. et al. Antifungal drug susceptibility and phylogenetic diversity among *Cryptococcus* isolates from dogs and cats in North America. *J Clin Microbiol*. 2014; 52: 2061–2070.
15. Iqbal N, DeBess EE, Wohrle R et al. Correlation of genotype and in vitro susceptibilities of *Cryptococcus gattii* strains from the Pacific Northwest of the United States. *J Clin Microbiol*. 2010; 48: 539–544.
16. Byrnes EJ, 3rd Li W, Ren P et al. A diverse population of *Cryptococcus gattii* molecular type VGIII in southern Californian HIV/AIDS patients. *PLoS Pathog*. 2011; 7: e1002205.
17. CLSI. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard—third edition. *CLSI document M27-A3*. Clinical and Laboratory Standards Institute, Wayne, PA. 2008.
18. Mumberg D, Muller R, Funk M. Yeast vectors for the controlled expression of heterologous proteins in different genetic backgrounds. *Gene*. 1995; 156: 119–122.
19. Goetz RD, Woods RA. Yeast transformation by the LiAc/SS carrier DNA/PEG method. *Methods Mol Biol*. 2006; 313: 107–120.
20. Davidson RC, Cruz MC, Sia RA et al. Gene disruption by biolistic transformation in serotype D strains of *Cryptococcus neoformans*. *Fungal Genet Biol*. 2000; 29: 38–48.
21. Edlind TD, Katiyar SK. Mutational analysis of flucytosine resistance in *Candida glabrata*. *Antimicrob Agents Chemother*. 2010; 54: 4733–4738.
22. Ireton GC, Black ME, Stoddard BL. The 1.14 A crystal structure of yeast cytosine deaminase: evolution of nucleotide salvage enzymes and implications for genetic chemotherapy. *Structure*. 2003; 11: 961–972.
23. Ko TP, Lin JJ, Hu CY et al. Crystal structure of yeast cytosine deaminase. Insights into enzyme mechanism and evolution. *J Biol Chem*. 2003; 278: 19111–19117.
24. Florent M, Noel T, Ruprich-Robert G et al. Nonsense and missense mutations in FCY2 and FCY1 genes are responsible for flucytosine resistance and flucytosine-fluconazole cross-resistance in clinical isolates of *Candida lusitanae*. *Antimicrob Agents Chemother*. 2009; 53: 2982–2990.
25. Lee KT, So YS, Yang DH et al. Systematic functional analysis of kinases in the fungal pathogen *Cryptococcus neoformans*. *Nat Commun*. 2016; 7: 12766.
26. Papon N, Noel T, Florent M et al. Molecular mechanism of flucytosine resistance in *Candida lusitanae*: contribution of the FCY2, FCY1, and FUR1 genes to 5-fluorouracil and fluconazole cross-resistance. *Antimicrob Agents Chemother*. 2007; 51: 369–371.
27. McManus BA, Moran GP, Higgins JA, Sullivan DJ, Coleman DC. A Ser29Leu substitution in the cytosine deaminase Fca1p is responsible for clade-specific flucytosine resistance in *Candida dubliniensis*. *Antimicrob Agents Chemother*. 2009; 53: 4678–4685.
28. Paluszynski JP, Klassen R, Rohe M, Meinhardt F. Various cytosine/adenine permease homologues are involved in the toxicity of 5-fluorocytosine in *Saccharomyces cerevisiae*. *Yeast*. 2006; 23: 707–715.
29. Erbs P, Exinger F, Jund R. Characterization of the *Saccharomyces cerevisiae* FCY1 gene encoding cytosine deaminase and its homologue FCA1 of *Candida albicans*. *Current Genetics*. 1997; 31: 1–6.
30. Weber E, Rodriguez C, Chevallier MR, Jund R. The purine-cytosine permease gene of *Saccharomyces cerevisiae*: primary structure and deduced protein sequence of the FCY2 gene product. *Mol Microbiol*. 1990; 4: 585–596.
31. Kern L, de Montigny J, Jund R, Lacroute F. The FUR1 gene of *Saccharomyces cerevisiae*: cloning, structure and expression of wild-type and mutant alleles. *Gene*. 1990; 88: 149–157.
32. Pfaller MA, Messer SA, Boyken L et al. Global trends in the antifungal susceptibility of *Cryptococcus neoformans* (1990 to 2004). *J Clin Microbiol*. 2005; 43: 2163–2167.
33. Hagen F, Illnait-Zaragozi M-T., Bartlett K. H. et al. *In vitro* antifungal susceptibilities and amplified fragment length polymorphism genotyping of a worldwide collection of 350 clinical, veterinary, and environmental *Cryptococcus gattii* isolates. *Antimicrob. Agents Chemother*. 2010; 54: 5139–5149.
34. Espinel-Ingroff A, Aller AI, Canton E et al. *Cryptococcus neoformans-Cryptococcus gattii* species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole. *Antimicrob Agents Chemother*. 2012; 56: 5898–5906.
35. Govender NP, Patel J, van Wyk M et al. Trends in antifungal drug susceptibility of *Cryptococcus neoformans* isolates obtained through population-based surveillance in South Africa in 2002–2003 and 2007–2008. *Antimicrob Agents Chemother*. 2011; 55: 2606–2611.
36. Cogliati M. Global molecular epidemiology of *Cryptococcus neoformans* and *Cryptococcus gattii*: an atlas of the molecular types. *Scientifica (Cairo)*. 2013; 675213.
37. Hagen F, Khayhan K, Theelen B et al. Recognition of seven species in the *Cryptococcus gattii/Cryptococcus neoformans* species complex. *Fungal Genet Biol*. 2015; 78: 16–48.
38. Kwon-Chung KJ, Bennett JE, Wickes BL et al. The case for adopting the “species complex” nomenclature for the etiologic agents of cryptococcosis. *mSphere*. 2017; 2: e00357.
39. Cohen BA, Pilpel Y, Mitra RD, Church GM. Discrimination between paralogs using microarray analysis: application to the Yap1p and Yap2p transcriptional networks. *Mol Biol Cell*. 2002; 13: 1608–1614.
40. Chen YN, Lo HJ, Wu CC et al. Loss of heterozygosity of FCY2 leading to the development of flucytosine resistance in *Candida tropicalis*. *Antimicrob Agents Chemother*. 2011; 55: 2506–2514.
41. Costa C, Ponte A, Pais P et al. New mechanisms of flucytosine resistance in *C. glabrata* unveiled by a Chemogenomics analysis in *S. cerevisiae*. *PLoS one*. 2015; 10: e0135110.